Prolonged QT dispersion in inflammatory bowel disease

doi:10.3748/wjg.v19.i1.65

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3691)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

468

HTML

2808

Figures (1-1)

198

Tables (1-4)

217

Sum=3691

Jan 7, 2013 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 7, 2013; 19(1): 65-71
Published online Jan 7, 2013. doi: 10.3748/wjg.v19.i1.65

Table 1 Characteristics of patients with Crohn’s disease, and the relationship between QT prolongation n (%)

	CD QT prolongation		Test values
	-	+	χ²	P value
Diagnosis period (yr)	26.47 ± 34.27	27.2 ± 32.88	Z = 0.31	0.74
Family history			0.97	0.61
None	30 (83.3)	5 (100)
CD	3 (8.3)
Colon cancer	3 (8.3)
Operation			2.11	0.14
Yes	5 (13.88)	2 (40)
No	31 (86.11)	3 (60)
Age at diagnosis (yr)			3.01	0.22
< 17	2 (5.6)
17-40	33 (91.70)	4 (80)
> 40	1 (2.80)	1 (20)
Disease behavior			23.35	0.000^b
Non-stricturing Non penetrating	22 (61.1)	1 (20)
Stricturing	14 (38.9)	1 (20)
Penetrating	-	3 (60)
Disease location			0.55	0.75
İleal	12 (33.3)	1 (20)
Colonic	1 (2.80)	-
İleocolonic	23 (63.90)	4 (80)
CDAI value			0.013	0.91
CDAI < 150	28 (77.7)	4 (80)
CDAI ≥ 150	8 (22.2)	1 (20)
Drug use			0.13	0.71
Used	26 (72.2)	4 (80)
Not used	10 (27.8)	1 (20)
5-ASA			0.23	0.62
Used	11 (30.6)	1 (20)
Not used	25 (69.4)	4 (80)
CS			0.97	0.32
Used	30 (83.3)	5 (100)
Not used	6 (16.7)	-
IS			0.13	0.71
Used	26 (72.2)	4 (80)
Not used	10 (27.8)	1 (20)
Smoking			0.66	0.72
Yes	21 (58.3)	2 (40)
No	9 (25)	2 (40)
Quit	6 (16.7)	1 (20)
Alcohol			2.08	0.35
Yes	9 (25)	-
No	25 (69.4)	5 (100)
Quit	2 (5.6)	-

^bP < 0.01, χ² test and Z: Mann-Whitney U test. CD: Crohn’s disease; CDAI: Crohn’s disease activity index; 5-ASA: 5-aminosalicylic acid; CS: Corticosteroid; IS: immunosuppressive.

Table 2 Characteristics of patients with ulcerative colitis, and the relationship between QT prolongation n (%)

	UC QT prolongation		Test values
	-	+	χ²	P value
Diagnosis period (yr)	44.13 ± 42.60	45.67 ± 47.99		0.86
Family history			0.48	0.78
None	41 (77.4)	6 (66.7)
UC	8 (15.1)	2 (22.2)
Colon cancer	4 (7.5)	1 (11.1)
Operation			0.17	0.67
Yes	1 (1.9)	-
No	52 (98.1)	9 (100)
Extent of disease			3.49	0.32
Rectosigmoid	16 (30.18)	2 (22.22)
Left sided colon	10 (18.86)	4 (44.4)
Extensive	6 (11.32)	-
Pancolitis	21 (39.62)	3 (33.3)
Clinical activity			2.19	0.33
TW1 (mild activity)	34 (64.15)	8 (88.89)
TW2 (moderate activity)	17 (32.07)	1 (11.11)
TW3 (severe activity)	3.77	-
Drug use			0.09	0.75
Used	45 (84.9)	8 (88.89)
Not used	8 (15.09)	1 (11.11)
5-ASA			0.19	0.65
Used	9 (16.98)	1 (11.11)
Not used	44 (83.01)	8 (88.89)
CS			1.12	0.28
Used	47 (88.67)	9 (100)
Not used	6 (11.32)	-
IS			0.13	0.71
Used	49 (92.45)	8 (88.89)
Not used	4 (7.54)	1 (11.11)
Smoking			2.99	0.22
Yes	12 (22.64)	2 (22.2)
No	26 (49.05)	2 (22.2)
Quit	15 (28.30)	5 (55.56)
Alcohol
Yes	9 (16.98)	2 (22.2)	0.46	0.79
No	42 (79.24)	7 (77.78)
Quit	2 (3.77)	-

χ² test, Mann-Whitney U test. TW: Truelove-Witts clinical activity index; UC: Ulcerative colitis; 5-ASA: 5-aminosalicylic acid; CS: Corticosteroid; IS: Immunosuppressive.

Table 3 Crohn’s disease and control group, demographic, anthropometric and laboratory values and the relationship between QT prolongation

	CD QT prolongation (-)	CD QT prolongation (+)	Control	Test values
Male, n (%)	23 (63.9)	2 (40)	31 (66)	χ² = 1.31, P = 0.51
Female, n (%)	13 (36.1)	3 (60)	16 (34)	χ² = 1.31, P = 0.51
Age (yr)	36.80 ± 7.79	41.33 ± 7.66	41.21 ± 10.55	P = 0.53
SBP (mmHg)	109.72 ± 13.41	105 ± 20	102.74 ± 11.93	P = 0.071
DBP (mmHg)	69.72 ± 9.40	70 ± 10	71.11 ± 6.55	P = 0.62
Heart rate (beats/min)	77.13 ± 13.4	71.4 ± 12.23	74.80 ± 13.25	P = 0.36
BMI (kg/m²)	23.78 ± 4.90	25.38 ± 3.99	24.77 ± 3.43	P = 0.57
WC (cm) male	89 ± 7.88	91 ± 6.36	90.19 ± 4.99	P = 0.14
WC (cm) female	87.23 ± 5.45	92.33 ± 7.08	90.68 ± 5.18	P = 0.19
QTcd (ms)	39.69 ± 2.32	55.4 ± 2.88	38.68 ± 2.25	CD QT prolongation (-) vs (+), CD QT prolongation (+) vs control, ^bP = 0.000; CD QT prolongation (-) vs control, ^aP = 0.049
FPG (mg/dL)	89.31 ± 6.87	93.8 ± 10.75	87.6 ± 10.13	P = 0.078
Total-C (mg/dL)	187.89 ± 39.46	189.8 ± 21.28	185.68 ± 37.74	P = 0.65
Triglyceride (mg/dL)	116.51 ± 64.85	111 ± 33.12	97.98 ± 36.74	P = 0.50
HDL-C (mg/dL)	55.4 ± 12.69	60 ± 19.19	58.17 ± 14.74	P = 0.66
LDL-C (mg/dL)	121.05 ± 32.66	118.2 ± 9.78	119.02 ± 24.48	P = 0.77
Insulin (μU/mL)	6.44 ± 3.28	10.95 ± 6.10	5.68 ± 3.83	CD QT prolongation (-) vs (+), ^aP = 0.036; CD QT prolongation (-) vs control, ^aP = 0.027; CD QT prolongation (+) vs control, P = 0.16
HOMA-IR	1.42 ± 0.75	2.56 ± 1.43	1.31 ± 0.94	CD QT prolongation (-) vs (+), ^aP = 0.026; CD QT prolongation (-) vs control, P = 0.12; CD QT prolongation (+) vs control, ^aP = 0.023
Uric acid (mg/dL)	4.09 ± 0.86	4.26 ± 1.52	4.01 ± 1.05	P = 0.95

^aP < 0.05,

^bP < 0.01, χ² test, Mann-Whitney U test, Kruskall-Wallis test. CD: Crohn’s disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index; WC: Waist circumference; QTcd: Corrected QT dispersion; FPG: Fasting plasma glucose; C: Cholesterol; HDL: High density lipoprotein; LDL: Low density lipoprotein; HOMA-IR: Homeostasis model assessment of insulin resistance.

Table 4 Ulcerative colitis and control group, demographic, anthropometric, and laboratory values and the relationship between QT prolongation

	UC QT prolongation (-)	UC QT prolongation (+)	Control	Test values
Male, n (%)	25 (47.2)	5 (55.6)	31 (66)	χ² = 3.56, P = 0.16
Female, n (%)	28 (52.8)	4 (44.4)	16 (34)	χ² = 3.56, P = 0.16
Age (yr)	39.57 ± 11.58	48.67 ± 13.93	41.21 ± 10.55	P = 0.14
SBP (mmHg)	114.09 ± 8.73	125 ± 13.81	102.74 ± 9.93	UC QT prolongation (-) vs (+), ^aP = 0.012; UC QT prolongation (-) vs control, P = 0.51; UC QT prolongation (+) vs control, ^aP = 0.037
DBP (mmHg)	73.96 ± 6.88	74.44 ± 8.81	71.11 ± 6.55	P = 0.66
Heart rate (beats/min)	77.13 ± 13.4	71.4 ± 12.23	74.80 ± 13.25	P = 0.25
BMI (kg/m²)	25.22 ± 4.31	27.72 ± 9.11	24.77 ± 3.43	P = 0.18
WC (cm) male	94.92 ± 9.91	104.6 ± 22.67	93.19 ± 10.99	P = 0.59
WC (cm) female	92.75 ± 12.83	93.5 ± 10.96	90.68 ± 12.18	P = 0.54
QTcd (ms)	40.09 ± 2.34	55.1 ± 3.1	38.68 ± 2.25	UC QT prolongation (-) vs (+), UC QT prolongation (+) vs control, ^bP = 0.000; UC QT prolongation (-) vs control, ^bP = 0.003
FPG (mg/dL)	93.62 ± 9.02	95.11 ± 17.33	87.6 ± 10.13	P = 0.53
Total-C (mg/dL)	194.49 ± 34.31	214.33 ± 40.84	185.68 ± 37.74	P = 0.34
Triglyceride (mg/dL)	114.33 ± 53.89	120.11 ± 36.31	97.98 ± 36.74	P = 0.10
HDL-C (mg/dL)	54.62 ± 15.10	61.22 ± 14.95	58.17 ± 14.74	P = 0.38
LDL-C (mg/dL)	124.81 ± 24.41	137.552 ± 28.75	119.02 ± 24.48	P = 0.49
Insulin (μU/mL)	7.20 ± 4.54	10.88 ± 7.19	5.68 ± 3.83	UC QT prolongation (-) vs (+), ^aP = 0.031; UC QT prolongation (-) vs control, P = 0.43; UC QT prolongation (+) vs control, ^aP = 0.047
HOMA-IR	1.90 ± 1.09	2.94 ± 1.88	1.31 ± 0.94	UC QT prolongation (-) vs (+), ^aP = 0.011; UC QT prolongation (-) vs control, P = 0.51; UC QT prolongation (+) vs control, ^aP = 0.027
Uric acid (mg/dL)	4.31 ± 1.35	4.44 ± 1.29	4.01 ± 1.05	P = 0.12

^aP < 0.05,

^bP < 0.01, χ² test, Mann-Whitney U test, Kruskall-Wallis test. UC: Ulcerative colitis; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index; WC: Waist circumference; QTcd: Corrected QT dispersion; FPG: Fasting plasma glucose; C: Cholesterol; HDL: High density lipoprotein; LDL: Low density lipoprotein; HOMA-IR: Homeostasis model assessment of insulin resistance.

Citation: Yorulmaz E, Sezgin A, Yorulmaz H, Adali G, Ciftci H. Prolonged QT dispersion in inflammatory bowel disease. World J Gastroenterol 2013; 19(1): 65-71
URL: https://www.wjgnet.com/1007-9327/full/v19/i1/65.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i1.65